Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 177.83 USD 0.5%
Market Cap: 314.3B USD
Have any thoughts about
Abbvie Inc?
Write Note

Operating Margin
Abbvie Inc

27.8%
Current
33%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27.8%
=
Operating Profit
15.4B
/
Revenue
55.5B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Abbvie Inc
NYSE:ABBV
313.5B USD
28%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Amgen Inc
NASDAQ:AMGN
158.1B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
112B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.8B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.1B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
35B EUR
-22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
32.7B USD
-9%
Country US
Market Cap 313.5B USD
Operating Margin
28%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 158.1B USD
Operating Margin
19%
Country US
Market Cap 118B USD
Operating Margin
40%
Country US
Market Cap 112B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.8B AUD
Operating Margin
26%
Country US
Market Cap 82.1B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 35B EUR
Operating Margin
-22%
Country US
Market Cap 32.7B USD
Operating Margin
-9%
No Stocks Found

Abbvie Inc
Glance View

Market Cap
314.2B USD
Industry
Biotechnology

AbbVie Inc. is a global biopharmaceutical company that emerged from Abbott Laboratories in 2013, establishing itself as a key player in the healthcare sector with a strong focus on developing innovative therapies. Headquartered in North Chicago, Illinois, AbbVie specializes in immunology, oncology, neuroscience, and virology, boasting a diverse portfolio of products designed to address complex health challenges. Its flagship drug, Humira, has been a cornerstone of the company’s success, contributing significantly to its revenues since it was launched. However, with the expiration of Humira's patent, AbbVie is strategically transitioning its focus toward new treatments, including promising drugs in late-stage development and an expanding pipeline that aims to harness advanced technologies and unique therapeutic approaches. As an investor, AbbVie presents an intriguing opportunity due to its robust commitment to research and development, evidenced by substantial investments that have bolstered its product lineup. The company’s proactive measures to mitigate potential revenue loss from Humira's generics include the acquisition of Allergan in 2020, which expanded its presence in aesthetic medicine and neurology with successful brands like Botox. This move not only diversified its revenue streams but also solidified AbbVie’s competitive position in the biopharmaceutical landscape. With a commitment to delivering long-term value, strong dividend performance, and a focus on innovation, AbbVie is positioned to adapt and thrive amidst the evolving industry dynamics, making it a compelling consideration for investors seeking growth in the healthcare space.

ABBV Intrinsic Value
142.32 USD
Overvaluation 20%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27.8%
=
Operating Profit
15.4B
/
Revenue
55.5B
What is the Operating Margin of Abbvie Inc?

Based on Abbvie Inc's most recent financial statements, the company has Operating Margin of 27.8%.